8-K: Acasti Pharma Completes Enrollment in Pivotal Phase 3 Safety Trial for GTX-104

Acasti Pharma has completed patient enrollment in its Phase 3 STRIVE-ON safety trial for GTX-104, an injectable treatment for aneurysmal subarachnoid hemorrhage, with data readout expected in early 2025.

Summary

• Acasti Pharma has announced the completion of patient enrollment in its Phase 3 STRIVE-ON safety trial for GTX-104.
• The trial is a randomized, open-label study comparing GTX-104 to oral nimodipine in 100 patients hospitalized for aneurysmal subarachnoid hemorrhage (aSAH).
• Approximately 25 hospitals in the U.S. participated in the trial.
• The primary endpoint of the trial is safety, measured by comparing adverse events, including hypotension, between the two treatment groups.
• Acasti anticipates a data readout from the trial in early calendar 2025.
• The company plans to submit a New Drug Application (NDA) to the FDA in the first half of calendar 2025.
• GTX-104 is a novel injectable formulation of nimodipine designed to address the challenges of oral nimodipine administration for aSAH.
• The addressable market in the United States for GTX-104 is estimated to be about $300 million.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the successful completion of enrollment ahead of schedule, the potential of GTX-104, and the planned NDA submission. The company is clearly making progress on its key asset.

Positives

• The completion of enrollment in the STRIVE-ON trial was achieved ahead of the company's original expectations.
• GTX-104 has the potential to address significant challenges with oral nimodipine administration.
• GTX-104 may transform the standard of care for patients with aSAH.
• GTX-104 has shown significantly lower pharmacokinetic variability compared to oral nimodipine in previous trials.
• The company has received Orphan Drug Designation for GTX-104, providing seven years of marketing exclusivity post-launch in the United States.

Negatives

• The document does not explicitly mention any negative aspects of the trial or the company's performance.

Risks

• The success and timing of regulatory submissions for GTX-104 are subject to uncertainty.
• Regulatory requirements or developments could impact the outcome and timing of the NDA application.
• Changes to clinical trial designs and regulatory pathways could affect the project.
• Legislative, regulatory, political, and economic developments could impact the company.
• Actual costs associated with Acasti's clinical trials could differ from management's expectations.

Future Outlook

The company anticipates a data readout from the STRIVE-ON trial in early calendar 2025 and plans to submit an NDA to the FDA in the first half of 2025. They also mention the potential for licensing or selling other drug candidates.

Management Comments

• Prashant Kohli, CEO of Acasti, stated that the completion of enrollment in the STRIVE-ON trial is a significant milestone achieved ahead of original expectations.
• The CEO also expressed pride in the team's diligence and gratitude to the investigators for their support.
• Management believes that if approved, GTX-104 has the potential to transform the standard of care for patients with aSAH.

Industry Context

This announcement is significant in the context of rare disease drug development, as aSAH is a life-threatening condition with limited treatment options. The development of GTX-104, with its novel delivery method, could provide a significant advancement in the treatment of this condition. The company is also focusing on orphan drug designation which provides market exclusivity.

Comparison to Industry Standards

• The trial is comparing GTX-104 to oral nimodipine, which is the current standard of care for aSAH.
• The use of an injectable formulation is a novel approach, as oral administration can be challenging in unconscious or dysphagic patients.
• The company is targeting a $300 million addressable market in the US, which is a significant opportunity for a rare disease drug.
• Other companies developing treatments for aSAH include pharmaceutical giants such as Bayer, which also produces nimodipine. Acasti is attempting to improve on the delivery method of this existing drug.
• The company's focus on orphan drug designation is a common strategy for companies developing treatments for rare diseases, as it provides market exclusivity and other benefits.

Stakeholder Impact

• Shareholders may view this as positive news, as it indicates progress in the development of GTX-104.
• Patients with aSAH may benefit from a new treatment option if GTX-104 is approved.
• The company's employees are likely to be motivated by the progress of the clinical trial.

Next Steps

• The company will proceed with data analysis from the STRIVE-ON trial.
• A data readout from the trial is expected in early calendar 2025.
• The company plans to submit a New Drug Application (NDA) to the FDA in the first half of calendar 2025.

Key Dates

Keywords

GTX-104, aSAH, aneurysmal subarachnoid hemorrhage, Phase 3 trial, nimodipine, FDA, NDA, clinical trial, biopharma, Orphan Drug Designation